麻豆视频

Global Stents Market Trends and Insights

Rising Prevalence of Cardiovascular & Peripheral Arterial Diseases

Cardiovascular disorders caused 17.9 million deaths in 2024, equal to 32% of all global mortality, elevating demand for revascularization tools such as stents.^{[1]World Health Organization, 鈥淐ardiovascular Diseases (CVDs),鈥� WHO, who.int} Diabetes affected 537 million adults in 2025, accelerating atherosclerotic plaque progression and necessitating repeat interventions. In the United States, coronary artery disease affected 20.5 million adults in 2024, with annual PCI procedures surpassing 1 million.^{[2]American Heart Association, 鈥淗eart Disease and Stroke Statistics 鈥� 2024 Update,鈥� AHA, heart.org}Peripheral arterial disease touches 200 million people worldwide, but treatment rates remain below 15% in low-income nations, suggesting untapped pent-up need. Aging populations in Japan and Western Europe are presenting more complex multivessel disease, prompting thinner-strut device design. Emerging data also link prolonged exposure to PM2.5 above 100 碌g/m鲁 in parts of India and China to a 30% surge in acute coronary syndrome admissions.

Growing Demand for Minimally Invasive Percutaneous Interventions

Patients favor catheter-based therapy over surgical bypass owing to shorter stays and quicker recovery. Same-day discharge reached 22% of U.S. elective PCI cases in 2025, up from 8% in 2020, aided by radial access and refined anticoagulation.^{[3]Society for Cardiovascular Angiography and Interventions, 鈥淪ame-Day Discharge After Elective PCI,鈥� SCAI, scai.org} Drug-eluting stents now secure 18-month patency above 80% in diabetic superficial femoral artery cohorts, broadening peripheral indications. Neurovascular thrombectomy with adjunct flow-diverter implantation is reducing stroke disability when performed within a six-hour window. Outpatient migration is trimming per-case reimbursement, compelling manufacturers to negotiate volume-based contracts. The European Medicines Agency has fast-tracked devices incorporating novel polymers to cut required dual-antiplatelet therapy durations.

Technological Advancements in Drug-Eluting & Bioresorbable Stents

Next-generation coronary devices employ biodegradable coatings that release sirolimus-class agents over 3-6 months and then dissolve, easing long-term inflammation. Abbott re-launched Absorb trials in 2024 with optimized poly-L-lactic acid that fully hydrolyzes in 24 months. Boston Scientific鈥檚 polymer-free Eluvia won FDA clearance in 2025, recording late-lumen-loss of just 0.09 mm at one year. Ultra-thin (<70 碌m) cobalt-chromium struts improve deliverability without sacrificing radial force. Optical coherence tomography reveals angiography-guided implants are malapposed in 18% of cases, so vendors now bundle imaging consoles with stent sales.

Outpatient PCI Expansion Via ASC-Friendly Reimbursement Reforms

CMS added elective PCI to the ASC list in January 2024 with a national payment of USD 8,200, catalyzing a wave of 47 new cardiovascular centers in 2025. Facilities apply CathPCI risk scores to triage candidates, excluding those with left-ventricular ejection fraction below 30%. Radial access plus bivalirudin drives vascular complication rates below 1%, enabling walk-out discharge. Major private insurers rapidly mirrored CMS policy. Profit-sharing has encouraged physician-owned centers, redistributing facility fees away from hospitals.

Stringent Regulatory Approval & Post-Market Surveillance Demands

The FDA now requires five-year data on 1,500 patients for drug-eluting stent approvals, doubling timelines to 36 months and elevating per-device trial costs to USD 40 million. EU MDR enforcement since May 2024 mandates annual factory audits, producing a 14-month CE-renewal backlog. Japan鈥檚 PMDA permits conditional entry for bioresorbable scaffolds after two-year data but insists on manufacturer-funded registries. Administrative load favors incumbents with deep regulatory teams and deters venture-backed entrants.

In-Stent Thrombosis / Restenosis Risks & Related Litigation

Meta-analyses published in 2024 cited a 0.6% annual late-thrombosis rate for second-generation drug-eluting stents, equating to 6,000 U.S. events yearly. Dual-antiplatelet adherence drops to 62% at 18 months, amplifying risk. Class-action suits filed in 2025 over first-generation paclitaxel devices seek USD 200 million in damages. Neointimal hyperplasia drives 8-12% restenosis rates within two years, prompting costly repeat interventions. Regulators now direct manufacturers to embed thrombosis risk calculators in labeling.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Stent Type: Neurovascular Expansion Outpaces Coronary Maturity

Coronary devices retained 61.46% of the 2025 stents market share on the strength of entrenched use in ischemic heart disease. Growth, however, is leveling as drug-eluting penetration tops 90% and bare-metal applications shrink to graft lesions. Neurovascular stents are forecast to post an 8.46% CAGR through 2031, propelled by the widespread rollout of flow-diverter technology that safely treats wide-neck aneurysms without open surgery. Peripheral vascular implants benefit from an endovascular-first approach to limb salvage, with patency above 75% at three years when combined with drug-coated balloons.

Neurovascular momentum underscores a broader shift in the stents market toward complex, high-acuity indications, where reimbursement per case remains robust despite pricing pressure elsewhere. Gastrointestinal, urological, and airway segments together account for a small slice of the overall stents market size but are advancing rapidly as biodegradable polymers eliminate retrieval needs in palliative oncology settings. Bioresorbable coronary scaffolds, although still trial-restricted, are expected to re-enter commercialization on refined polymer chemistry backed by the ABSORB IV data set due in 2026.

By Material: Polymeric Platforms Tackle Long-Term Complications

Metallic alloys such as cobalt-chromium and platinum-chromium commanded 63.68% of 2025 revenue because they offer thin struts without sacrificing radial strength. Polymeric constructs are projected to climb at a 7.56% CAGR on rising surgeon confidence that resorbable devices reduce late thrombosis. Within that niche, poly-L-lactic acid dominates but newer blends featuring polycaprolactone are tuning degradation to 18-24 months, restoring vasomotion once support is no longer needed. 

Interest in natural biomaterials such as collagen coatings remains modest, yet they serve patients with metal hypersensitivity and pediatric congenital defects requiring temporary scaffolds. Polymer-free drug-eluting stents provide a tactical intermediate, keeping metallic reliability while dropping the inflammatory load of carrier polymers. This transition illustrates how the stents market size growth intertwines with material science breakthroughs.

By Mode of Delivery: Self-Expandable Designs Climb in Tortuous Anatomy

Balloon-expandable platforms led with 57.82% revenue in 2025 thanks to precise inflation control in rigid, calcified coronary lesions. Self-expandable nitinol models are forecast to outpace at an 8.31% CAGR as peripheral and neurovascular work shifts volume their way. These devices can recover a pre-programmed diameter after compression and ride out vessel flexion, a critical trait in femoral arteries experiencing 40% cyclical diameter change during walking. 

Carotid and renal segments are transitioning toward self-expandable architectures that maintain wall apposition as vessels remodel. Flow-diverter constructs, essentially tightly braided self-expandable mesh, redirect blood away from aneurysm sacs while keeping side branches patent. Hybrid balloon-plus-self designs for aortic bifurcations are being prototyped, though regulatory guidance is still emerging.

By End User: Ambulatory Centers Capture Same-Day Discharge Momentum

Hospitals continued to hold 69.22% of procedure revenue in 2025 because they treat multivessel and high-risk patients requiring surgical backup. Ambulatory surgical centers are predicted to rise at a 7.24% CAGR, energized by CMS policy and patient preference for shorter stays. Radial access provides sub-1% vascular complication rates, allowing six-hour observation windows. 

Cardiac clinics鈥攐ffice-based labs with limited anesthesia鈥攁re eyeing single-vessel, stable lesions but remain constrained by state regulations that reserve complex interventions for hospitals. In dense metropolitan areas, the margin differential motivates clinicians to form physician-owned ASCs, recapturing facility fees previously ceded to hospitals. Overseas, Germany and the United Kingdom have begun pilot ASC PCI programs, though hospital-centric rules slow uptake.

Geography Analysis

North America led with 32.58% of 2025 revenue as sophisticated imaging suites, AI-enabling software, and premium bioresorbable launches kept average selling prices elevated. U.S. procedure counts are steady, but downward price renegotiations with group purchasing organizations are tempering top-line growth. Canada鈥檚 single-payer system is slower to adopt bioresorbables, yet provincial health authorities are funding robotics pilots to offset rural cardiologist shortages.

Asia-Pacific is projected to deliver a 6.36% CAGR to 2031 and will likely overtake Europe in absolute revenue by late forecast. China鈥檚 procurement program dropped unit prices to USD 97, propelling a 140% spike in volumes as rural cath-lab build-outs captured previously untreated cases. India performed 1.2 million coronary interventions in 2025 after sustained price caps lowered out-of-pocket costs below catastrophic thresholds. Southeast Asian ministries are drafting copycat tenders, signaling sustained double-digit unit growth even if revenue per case compresses.

Europe faces budget ceilings and growing preference for drug-coated balloons that cost 40% less than metallic drug-eluting stents. Germany, France, and the United Kingdom together make up 60% of regional consumption, yet price erosion dominates as national health services pursue bundled cardiology payments. Japan鈥檚 ultra-aged demographic is fueling peripheral and neurovascular demand, but biannual fee schedule reductions limit monetization. The Middle East and Africa leverage oil-funded investment in catheterization labs, but a dearth of trained interventionists keeps procedure density low. South America鈥檚 public-sector expansion lifts basic coronary volumes, although currency swings and tariff burdens complicate supply chains in Brazil and Argentina.

Regulatory Landscape

Drug-eluting coronary stents are regulated as combination products in the United States, typically requiring FDA Premarket Approval (PMA) alongside expanded clinical and post-market evidence. Within the study period, the FDA tightened expectations for long-term follow-up for drug-eluting stents, and in February 2026 the agency implemented the Quality Management System Regulation (QMSR). The change aligns medical-device quality requirements with ISO 13485:2016 and affects design controls, supplier qualification, and manufacturing traceability for stent manufacturers and their contract partners.

In Europe, stents fall under the Medical Device Regulation (EU) 2017/745 (MDR), with additional requirements for drug-device combinations, including Notified Body opinion workflows under MDR Article 117 for integral products, and active vigilance guidance applied to coronary stents. MDR enforcement has increased certification and audit intensity, and May 2026 brought additional operational milestones tied to EUDAMED module use and MDR transition requirements for certain Class III implantable pathways. Compliance demands also interact with trade policy: China adjusted 2026 import tariffs on certain medical components relevant to stent manufacturing materials, while European industry bodies publicly opposed proposed US Section 301 tariff actions in mid-2026 due to potential supply-chain disruption for globally sourced medical technologies.

Value Chain Analysis

The stents value chain starts with upstream specialty materials and chemicals, including cobalt-chromium and platinum-chromium tubes for balloon-expandable platforms, nitinol tubing for self-expandable designs, and drug-polymer inputs for drug-eluting systems. Core manufacturing includes precision laser cutting, electropolishing, surface modification, drug coating (or polymer-free drug reservoirs), crimping onto delivery systems, and sterilization (commonly ethylene oxide), followed by packaging, labeling, and lot release under device-grade quality systems. Regulatory architecture shapes how these steps are documented and controlled: in the United States, the FDA Office of Combination Products coordinates oversight for drug-eluting cardiovascular stents, while in the European Union, MDR requirements, including Article 117 considerations for integral drug-device combinations, drive additional technical documentation and Notified Body interactions.

Midstream constraints have increasingly focused on capacity and lead-time volatility for specialty alloys and finishing steps, particularly for nitinol bars and tubing, where extended lead times during 2024-2025 have been reported due to post-processing dependencies and competing industrial demand. This has reinforced dual-sourcing, safety-stock strategies, and selective vertical integration across large OEMs and key suppliers, especially for materials and critical finishing operations. Downstream, manufacturers sell through direct hospital and ambulatory accounts and via distributors in tender-heavy markets. Buyer power is amplified by group purchasing organizations, national procurement programs, and government price ceilings in markets such as China and India, pushing vendors toward volume-based contracting, bundled imaging or workflow offerings, and localized assembly or registration strategies to maintain access and continuity of supply.

Market Opportunities and Future Outlook

A key whitespace is the intersection of outpatient migration and complex-lesion enablement. Same-day discharge PCI adoption and the shift of selected cases into ambulatory surgical centers change purchasing patterns toward standardized, high-throughput stent platforms and compatible imaging or procedural workflows. In the United States, CMS policy that added elective PCI to the ASC list (January 2024) has already supported new cardiovascular center buildouts, creating a clearer commercial lane for vendors that can support ASC credentialing needs, inventory efficiency, and consistent clinical performance under tighter per-case economics.

Product and geographic opportunity also shows up in next-generation drug-eluting and bioresorbable or absorbable-polymer designs targeting late adverse events and potentially shorter antiplatelet therapy considerations, alongside expansion into peripheral, venous, and neurovascular adjacencies. In 2026, several regulatory and clinical signals supported this direction: Kossel Medtech reported NMPA approval for its MiStent sirolimus-eluting absorbable-polymer coronary stent in April 2026, Solaris Endovascular received FDA Breakthrough Device Designation in May 2026 for a drug-eluting covered stent for dialysis access, and Latin American access pathways were highlighted by Sino Medical Sciences receiving INVIMA approval in Colombia (June 2026) for its HT Supreme drug-eluting stent. On the compliance side, the FDA QMSR implementation in February 2026 and evolving EU MDR frameworks, including Well-Established Technologies list expansion activity during 2026, are raising the value of scalable quality systems and strong technical documentation. That favors manufacturers that can industrialize evidence generation while keeping cost and supply continuity aligned to tender-driven purchasing.